TLDR The Federal Reserve held interest rates steady at 3.5% to 3.75% on Wednesday, marking the first pause since July Two Fed officials dissented and voted for TLDR The Federal Reserve held interest rates steady at 3.5% to 3.75% on Wednesday, marking the first pause since July Two Fed officials dissented and voted for

Federal Reserve Holds Rates Steady as Dollar Weakens to Four-Year Low

2026/01/29 15:42
3 min read

TLDR

  • The Federal Reserve held interest rates steady at 3.5% to 3.75% on Wednesday, marking the first pause since July
  • Two Fed officials dissented and voted for a 25-basis-point rate cut instead
  • The US dollar hit four-year lows this week after its worst annual performance since 2017
  • Bitcoin remained near $89,500 following the decision, while gold reached record levels near $5,300 per ounce
  • Markets now price the probability of rate cuts at below 50% for the next two Fed meetings

The Federal Reserve kept interest rates unchanged on Wednesday, leaving the federal funds rate between 3.5% and 3.75%. The Federal Open Market Committee voted to pause rate cuts for the first time since July.

The decision was widely expected by investors. Markets priced in no change at nearly 99% heading into the meeting.

The Fed cited inflation concerns in its policy statement. Officials said job gains have remained low and unemployment has shown signs of stabilization. The statement also noted that inflation remains “somewhat elevated.”

Two officials broke from the majority decision. Recent Trump appointee Stephen Miran and Chris Waller both voted in favor of a 25-basis-point rate cut.

Bitcoin (BTC) PriceBitcoin (BTC) Price

Bitcoin traded just under $89,500 after the announcement. US stocks showed little change following the decision. Gold continued climbing, reaching near record levels at $5,300 per ounce.

The US dollar has weakened in recent days. The Bloomberg Spot Dollar Index fell to four-year lows this week. The dollar posted its worst annual performance since 2017.

Dollar Weakness and Market Impact

Some analysts believe the dollar’s slide could effectively ease financial conditions. Market commentator The Kobeissi Letter called it “a clear signal that President Trump is willing to tolerate a weaker Dollar to push rates lower and boost US exports.”

David Ingles from Bloomberg TV APAC agreed. He said President Trump may be “cutting rates on the Fed’s behalf by letting the dollar slide.”

The cryptocurrency market has shown mixed reactions. Bitcoin and other digital assets have been volatile as traders debate the impact of future rate decisions.

Analysts point to an inverse relationship between Bitcoin and the US Dollar Index. A stronger dollar typically weighs on cryptocurrencies and other risk assets.

Rate Cut Expectations Fade

Market expectations for rate cuts have changed drastically. In mid-November, prediction markets put the odds of a January cut above 40%. Those odds fell to nearly zero by this week’s meeting.

Markets are not expecting rate cuts at the March meeting. CME FedWatch places those odds at just 16%. The probability rises to about 30% for the April meeting.

Nick Ruck from LVRG Research commented on the decision. He said the Fed’s hold reflects persistent inflation concerns and a stabilizing economy. This could result in near-term volatility for crypto markets.

Jerome Powell held a press conference at 2:30 pm ET following the announcement. Investors watched for clues about the central bank’s future plans.

The post Federal Reserve Holds Rates Steady as Dollar Weakens to Four-Year Low appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26